Effect of nifedipine, captopril and prazosin on secretory function of pancreatic β-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics

Diabetes Research and Clinical Practice

Volumn 33, Issue 1, 1996, Pages 59-66

  Jasik, Mariusz ^a   Kasperska Dworak, Anna ^a   Czyzyk, Artur ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

C peptide; Captopril; Diabetes; Hypertension; Insulin; Nifedipine; Prazosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; NIFEDIPINE; PRAZOSIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PANCREAS FUNCTION;

EID: 0030175217     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-8227(96)01258-2     Document Type: Article

References (19)

1. [1] Christlieb, A.R. (1973) Diabetes and hypertensive vascular disease. Am. J. Cardiol. 32, 592-597.
2. [2] The Working Group on Hypertension in Diabetes (Runyan, J.W. Chairman). (1987) Statement on Hypertension in Diabetes Mellitus. Arch. Int. Med. 147, 1165-1166.
3. [3] Walford, S., Page, M.M. and Allison, S.P. (1980) The influence of renal threshold on the interpretation of urine tests for glucose in diabetic patients. Diabetes Care 3, 672-674.
4. [4] Conard, V. (1955) Mesure de l'assimilation due glucose Bases the 'oretiques et applications cliniques. Acta Med. Belg., Bruxelles.
5. [5] Abadie, E., Villette, J.M., Gauville, C., Tabuleau, F., Fiet, J. and Passa, P. (1985) Effects of nifedipine on carbohydrate metabolism in the non-insulin-dependent diabetic. Diabetes Metab. 11, 141-146.
6. [6] Devis, G., Somers, G., Van Obberghen, E. and Malaisse, W.J. (1970) Calcium antagonists and islet function. Inhibition of insulin release by verapamil. Diabetes 24, 547-551.
7. [7] Greenwood, R.H. (1982) Hyperglycaemic effect of nifedipine. BMJ 284, 50.
8. [8] Charles, S., Ketelslegers, J.M., Buysschaert, M., Lambert, E.A. (1989). Hyperglycaemic effect in nifedipine. BMJ 283, 19-20.
9. [9] Trost, B.N., Weidmann, P. and Beretta-Picoli, C. (1985) Antihypertensive Therapy in Diabetic Patients. Hypertension 7 (Suppl II), II 102-II 108.
10. 2+ Channel Antagonists, and α-Adrenergic Blockers and Glucose and Lipid Metabolism in NIDDM Patients With Hypertension. Diabetes 44, 665-71.
11. [11] Harano, Y., Kageyama, A., Hirose, J., et al. (1995) Improvement of Insulin Senitivity for Glucose Metabolism with the Long-Acting Ca-Channel Blocker Amplodipine in Essential Hypertensivite Subjects. Metabolism 44, 315-319.
12. [12] Sheu, W.H.H., Swislocki, A.L.M., Hoffman, B. et al. (1991) Comparison of the effects of at atenolol and nifedipine on glucose, insulin and lipid metabolism in patients with hypertension. Am. J. Hypertens. 4, 199-205.
13. [13] Ferriere, M., Lachkar, H., Richard, J.L., Bringer, J., Orsetii, A. and Mirouze, J. (1985) Captopril and insulin sensitivity. Ann. Int. Med. 102, 134-135.
14. [14] Rett, K., Wickayr, M. and Dietze, G.L. (1988) Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides and captopril. N. Engl. J. Med. 319, 1609.
15. [15] Zusman, R.M. (1993) Angiotensin-Converting Enzyme Inhibitors: More Different Than Alike? Am. J. Cardiol. 72, 25H-36H.
16. [16] Chan, J.C.N, Yeung, V.T.F, Leung, D.H.Y, et al. (1994) The Effects of Enalapril and Nifedipine on Carbohydrate and Lipid Metabolism in NIDDM. Diabetes Care 17, 859-862.
17. [17] Hsueh, W.A. and Buchanan, T.A. (1994) Obesity and hypertension. Endocr. Metab. Clin. North Am. 23, 405-27
18. [18] Canbien, F. and Plouin, P.F. (1985) Prazosin does not alter levels of plasma lipids, glucose and insulin. J. Cardiovasc. Pharmacol. 7, 516-519.
19. [19] Shionoiri, H., Noda, K., Miyamoto, K., et al. (1986). Glucose tolerance during chronic prazosin therapy in patients with essential hypertension. Curr. Ther. Res. 40, 171-180.